Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial

Jarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott J Antonia

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology